Abstract
Patients who develop heparin-induced thrombocytopenia (HIT) are at increased risk for morbidity and mortality if the disorder is not recognized and treated early. Upon initial suspicion of HIT, providers should promptly discontinue all heparin products and initiate an alternative form of anticoagulation without waiting for diagnostic test results confirming the presence of HIT antibodies. The direct thrombin inhibitor, argatroban (Argatroban), is a reasonable alternative anticoagulant in patients with HIT, based on its proven safety and efficacy, ease of use, and consistent response rate between individuals. Further clinical trials are warranted to evaluate and expand the use of argatroban in other thrombotic states.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
